Nyxoah SA PE Ratio 2021-2024 | NYXH
Current and historical p/e ratio for Nyxoah SA (NYXH) from 2021 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Nyxoah SA PE ratio as of November 20, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Nyxoah SA PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2024-11-19 | 8.13 | 0.00 | |
| 2024-09-30 | 9.55 | $-1.87 | 0.00 |
| 2024-06-30 | 6.97 | $-1.61 | 0.00 |
| 2024-03-31 | 13.49 | $-1.64 | 0.00 |
| 2023-12-31 | 4.64 | $-1.68 | 0.00 |
| 2023-09-30 | 7.05 | $-1.79 | 0.00 |
| 2023-06-30 | 8.01 | $-1.74 | 0.00 |
| 2023-03-31 | 7.47 | $-1.25 | 0.00 |
| 2022-12-31 | 4.99 | $-0.97 | 0.00 |
| 2022-09-30 | 6.30 | $-0.74 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.000B | $0.005B |
| Nyxoah SA is a medical technology company. It focused on the development and commercialization of solutions to treat Obstructive Sleep Apnea. Nyxoah SA is based in Belgium. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tempus AI (TEM) | United States | $8.497B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $5.276B | 164.53 |
| Hims & Hers Health (HIMS) | United States | $5.141B | 130.72 |
| Privia Health (PRVA) | United States | $2.533B | 211.10 |
| Enovis (ENOV) | United States | $2.529B | 17.15 |
| IRhythm Technologies (IRTC) | United States | $2.362B | 0.00 |
| Azenta (AZTA) | United States | $2.001B | 99.78 |
| Omnicell (OMCL) | United States | $1.964B | 64.26 |
| Clover Health Investments (CLOV) | United States | $1.644B | 0.00 |
| 10x Genomics (TXG) | United States | $1.643B | 0.00 |
| Schrodinger (SDGR) | United States | $1.378B | 0.00 |
| Phreesia (PHR) | United States | $1.072B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.650B | 0.00 |
| Standard BioTools (LAB) | United States | $0.562B | 0.00 |
| Talkspace (TALK) | United States | $0.522B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.520B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.483B | 83.60 |
| Health Catalyst (HCAT) | United States | $0.459B | 0.00 |
| TruBridge (TBRG) | United States | $0.244B | 71.22 |
| Pulmonx (LUNG) | United States | $0.237B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.214B | 0.00 |
| American Well (AMWL) | United States | $0.122B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.107B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.075B | 0.00 |
| HeartBeam (BEAT) | United States | $0.067B | 0.00 |
| 111 (YI) | China | $0.053B | 0.00 |
| CareCloud (CCLD) | United States | $0.046B | 0.00 |
| Zepp Health (ZEPP) | China | $0.040B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.040B | 0.00 |
| Outset Medical (OM) | United States | $0.039B | 0.00 |
| Movano (MOVE) | United States | $0.020B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.019B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.013B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.012B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.010B | 0.00 |
| Precipio (PRPO) | United States | $0.009B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.006B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.004B | 0.00 |
| Syra Health (SYRA) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.002B | 0.00 |
| Zhongchao (ZCMD) | China | $0.002B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |